Natera, Inc. (NTRA) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST
Company Participants
Mike Brophy – Chief Financial Officer
Conference Call Participants
Douglas Schenkel – Wolfe Research, LLC
Presentation
Douglas Schenkel
Wolfe Research, LLC
All right. So last run of the day. I’m Doug Schenkel. I lead Wolfe’s life science tools and diagnostics effort. It is my pleasure to have Mike Brophy of Natera with us. Mike, thanks for making the trip.
Mike Brophy
Chief Financial Officer
Yes. Thanks for having me here.
Question-and-Answer Session
Douglas Schenkel
Wolfe Research, LLC
We really appreciate it. So Natera is a leading diagnostic company focused on leveraging cell-free DNA technology across prenatal testing. And more in focus these days is the market leader, a pioneer in really advancing the field of minimal residual disease testing or MRD. So again, thanks for being here, Mike.
Mike Brophy
Chief Financial Officer
Yes. No, thanks for having me.
Douglas Schenkel
Wolfe Research, LLC
Lots to cover. I know we won’t get through all of it. And between the 2 of us, we have a hard time doing that. But I think it’s a good problem to have in the case of Natera because there’s so many great things going on right now. I thought we would spend a few minutes just doing kind of a state of the company to kick off. Then I do want to spend no surprise, a bit of time talking about where we are in MRD in terms of market penetration, competitive dynamics and some reimbursement developments fairly recently.
And then a more recent announcement, really leaning in more on early cancer detection. I think it makes sense to spend a little bit of time there.
Mike Brophy
Chief Financial Officer
Okay.
Douglas Schenkel
Wolfe Research, LLC
Read the full article here
